Project introduction here

OBJECTIVE 1. Understand the effect of antimicrobial exposure on the development of antimicrobial resistance for common pathogens

OBJECTIVE 2. Describe the in vivo effect of different infection pathologies on plasma and infection site antimicrobial PK (Projects 2-8)

Project 2a. Clinical PK study. Intensive-sampled infection site PK of meropenem, piperacillin,
ceftriaxone and penicillin-G in mechanically ventilated patients with ventilator-associated or
community-acquired pneumonia.

Project 2b. Clinical PK study. Multi-national sparse-sampled infection site PK of various
antimicrobials in patients with ventilator-associated pneumonia

Project 3a. Clinical PK study. SaMpling Antibiotics in Renal Replacement Therapy
(SMARRT).

Project 3b. Clinical PK study – Ex vivo RRT studies to accurately quantify the effect of RRT
settings on antimicrobial clearance

Project 4. Clinical PK study. Antimicrobial PK
in lung transplant, bone marrow transplant and
cystic fibrosis patients

Project 5. Clinical PK study. Flucloxacillin and
lincomycin PK in burns patients

Project 6. Clinical PK study. Multinational study of echinocandin and triazole antifungal PK
in ICU

Project 7. Clinical PK study. Antimicrobial PK in critically ill paediatric patients

Project 8. Clinical PK study. Multi-centre study of antimicrobial PK in obese critically ill
patients

 

OBJECTIVE 3. Define antimicrobial doses that prevent the development of resistance

Project 9. Combine dynamic in vitro resistance data (Project 1) with in vivo clinical PK data
(Projects 2-8) into robust pharmacostatistical models for innovative antimicrobial doses

OBJECTIVE 4. Test patient tolerability and capacity to suppress the emergence of resistance of novel antimicrobial doses in clinical trials and measure cost-effectiveness

Project 10 - Patient tolerability of novel antimicrobial doses. Multi-centre study of feasibility of therapeutic drug monitoring (TDM) optimisation of β-lactams for critically ill, burns and transplant patients.

OBJECTIVE 5. Undertake targeted clinical trials to determine the effect of PK/PD-guided interventions on clinical outcomes (Projects 11 & 12)

Project 11. Clinical outcome study. Multinational study of clinical outcomes of continuous infusion versus intermittent beta-lactam antibiotic administration in critically ill patients with severe sepsis and not receiving RRT.

Project 12. Clinical outcome study. Clinical outcomes of TDM-guided dose personalisation of piperacillin and combination chemotherapy for ICU patients with Gram-negative pneumonia

OBJECTIVE 6. Improve the patient experience for novel treatment of infections through consumer participation in CRE research

Project 13. Develop informed, trained consumer groups whose members participate as
partners in CRE research projects and processes